RPRX — Royalty Pharma Share News
0.000.00%
Last trade - 00:00- $36.72bn
- $47.80bn
- $2.38bn
Brief: Royalty Pharma Announces Pricing Of $1.5 Billion Of Senior Unsecured Notes
Agios climbs on $905 mln deal with Royalty Pharma for brain tumor treatment
Brief: Cytokinetics And Royalty Pharma Announce Expanded Strategic Funding Collaboration Of Up To $575 Mln
Royalty Pharma PLC reports results for the quarter ended in March - Earnings Summary
Brief: Royalty Pharma To Acquire Royalty Interest In Sanofi’S Frexalimab
Royalty Pharma PLC reports results for the quarter ended in December - Earnings Summary
Brief: Royalty Pharma Reports Q4 And Full Year 2023 Results
Royalty Pharma PLC expected to post earnings of $1.01 a share - Earnings Preview
Brief: Royalty Pharma Highlights Accomplishments And Provides Business Update
Brief: Royalty Pharma Unit Entered Into Amendment No.3 To Amended And Restated Revolving Credit Agreement
Brief: Teva And Royalty Pharma Collaborate To Further Accelerate Olanzapine Lai Program
Brief: Royalty Pharma Raises 2023 Guidance Adjusted Cash Receipts Expected To Be $2.95 Bln To $3.00 Bln
Brief: Royalty Pharma Q3 Net Income USD 122 Million
U.S. STOCKS ON THE MOVE-American Airlines, Netflix, Tesla
Brief: Royalty Pharma To Purchase Up To $1.5 Bln of PTC Therapeutics’ Royalty on Evrysdi
PTC Therapeutics and Royalty Pharma climb on new royalty deal
Royalty Pharma to pay $1 bln for Roche's SMA drug royalties (updated)
Brief: Royalty Pharma And Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Brief: Ascendis Pharma And Royalty Pharma Enter Into $150 Million Royalty Funding Agreement